

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**(1) PROPOSED ADOPTION OF SHARE OPTION SCHEME OF
A SUBSIDIARY**
**(2) PROPOSED GRANT OF SHARE OPTIONS OF
A SUBSIDIARY**

Reference is made to the announcements of 山東威高集團醫用高分子製品股份有限公司 (Shandong Weigao Group Medical Polymer Company Limited*) dated 22 September 2017 and 24 January 2018 (the “**Announcements**”) in relation to the formation of WW Medical and Healthcare Company Limited (“**WW Medical**”) for the acquisition of Argon Medical Devices Holdings, Inc. (“**Argon**”). Capitalised terms used herein have the same meanings as those defined in the Announcements.

**(1) PROPOSED ADOPTION OF SHARE OPTION SCHEME OF A
SUBSIDIARY**

WW Medical proposes to adopt a share option scheme of WW Medical (the “**WW Medical Share Option Scheme**”).

* For identification purpose only

As WW Medical is a subsidiary of the Company, the WW Medical Share Option Scheme is a share option scheme governed by Chapter 17 of the Listing Rules. Accordingly, the adoption of WW Medical Share Option Scheme is subject to the approval by shareholders of the Company (the “**Shareholders**”) in accordance with Rule 17.1(4) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

(2) PROPOSED GRANT OF SHARE OPTIONS OF A SUBSIDIARY

Subject to the WW Medical Share Option Scheme becoming effective, 1,200,000 share options of WW Medical (the “**WW Medical Share Options**”) are proposed to be granted to Mr. George A. Leondis (“**Mr. Leondis**”), who is a director and the chief executive officer of Argon (the “**Proposed Grant**”).

A summary of the terms of the Proposed Grant are set out below.

Date of grant	:	on the date of the passing of the ordinary resolution to approve the Proposed Grant.
Conditions of grant	:	(a) the Shareholders passing an ordinary resolution to approve the adoption of the WW Medical Share Option Scheme; and (b) the Shareholders passing an ordinary resolution to approve the Proposed Grant.
Exercise price	:	U.S.\$10.0 per WW Medical Share, which was determined with reference to the pro-rata total cash consideration paid by the Company for the formation of WW Medical for the acquisition of Argon, taking into account the relevant costs and expenses involved.
Number of WW Medical Share Options	:	1,200,000 WW Medical Share Options, with each WW Medical Share Option entitling Mr. Leondis to subscribe for one share in the capital of WW Medical designated as common shares of par value of U.S.\$0.001 per share (the “ WW Medical Shares ”).

Upon full exercise of the WW Medical Share Options, 1,200,000 WW Medical Shares, representing 2.61% of the total issued shares of WW Medical as at the date of this announcement and 2.54% of the total issued shares of WW Medical as enlarged by the issue of the WW Medical Shares under the Proposed Grant.

Exercise period : exercisable within a period of ten years from the date of grant, subject to the vesting schedule.

Vesting schedule : (a) 25% of the WW Medical Share Options shall vest and be exercisable on the first anniversary of the grant date;

(b) an additional 25% of the WW Medical Share Options shall vest and be exercisable on the second anniversary of the grant date;

(c) an additional 25% of the WW Medical Share Options shall vest and be exercisable on the third anniversary of the grant date; and

(d) the remaining 25% of the WW Medical Share Options shall vest and be exercisable on the fourth anniversary of the grant date.

Vesting of the WW Medical Share Options is conditional upon achievement of certain performance targets.

As at the date of this announcement, there are 46,000,000 WW Medical Shares in issue. Upon full exercise of the WW Medical Share Options, 1,200,000 WW Medical Shares, representing 2.61% of the total issued shares of WW Medical as at the date of this announcement.

No option has been granted to Mr. Leondis under any share option scheme of the Company in the 12 months immediately preceding the date of grant. Mr. Leondis is the President and Chief Executive Officer of Argon. The Proposed Grant exceeds 1% of the WW Medical Shares in issue. Accordingly, the Proposed Grant would be subject to the approval of the Shareholders at a general meeting pursuant to the Note to Rule 17.03(4) of the Listing Rules.

DESPATCH OF CIRCULAR AND EGM

A circular setting out further details of (i) WW Medical Share Option Scheme; (ii) the Proposed Grant; and (iii) the notice of extraordinary general meeting (the “EGM”) will be despatched to the Shareholders on or about 28 February 2018.

CLOSURE OF REGISTER OF MEMBERS

For the purpose of determining the list of Shareholders who are entitled to attend and vote at the EGM which is scheduled to be held on Monday, 16 April 2018, the register of members of the Company will be closed from Thursday, 15 March 2018 to Saturday, 14 April 2018 (both days inclusive). No transfer of shares of the Company will be registered during this period.

In order to qualify for attending the EGM, Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company’s H share registrar, Tricor Standard Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong, for registration no later than 4:30 p.m. on Wednesday, 14 March 2018.

By Order of the Board

Shandong Weigao Group Medical Polymer Company Limited

Zhang Hua Wei

Chairman

Weihai, Shandong, the PRC, 26 February 2018

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)